Antares Pharma, Inc. has received a second $5 million milestone payment from LEO Pharma in connection with the launch of OTREXUP. In November 2013, the companies entered an exclusive license and promotion agreement for OTREXUP (methotrexate) for symptomatic control of severe recalcitrant psoriasis in adults, under which Antares is eligible to receive as much as $20 million in milestone payments. LEO Pharma is responsible for all promotion and marketing costs in dermatology.    “We are excited th...